



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3273 9133
Facsimile: + 61 7 3375 1168
www.tbgbio.com

6 April 2020

ASX Announcement
Update on TBG Xiamen COVID-19 Virus Diagnostic Test Kit

TBG Diagnostics Limited ("Company") refers to its announcement dated 18 March 2020 in relation to the receipt of CE Mark approval of TBG Biotechnology Xiamen Inc ("TBG Xiamen")'s COVID-19 Virus Diagnostic Kits to enable TBG Xiamen to sell and export its COVID-19 Virus Diagnostic Kits to the European Economic Area. The Company has a 46.65% interest in the equity of TBG Xiamen, which is a China based molecular diagnostics company.

The Company has recently been advised that the Chinese Government has now banned the export of all COVID-19 diagnostics kits that have not obtained the required China medical device product registration certification.

TBG Xiamen's COVID-19 Virus Diagnostic Kits do not currently have China medical device product registration certification required under the new export requirements as recently announced by the Chinese Government, therefore TBG Xiamen are currently unable to sell and export their COVID-19 Nucleic Acid Diagnostics Kits from China. Without the China medical device product registration certification, TBG Xiamen is also currently unable to sell their COVID-19 Nucleic Acid Diagnostics Kits within China.

While TBG Xiamen has received interest from several buyers, in light of these new restrictions no COVID-19 Nucleic Acid Diagnostics Kits will be exported or sold while these restrictions remain in place or until TBG Xiamen receives the required certifications for sale and export.

TBG Xiamen intends to apply for the relevant regulatory approvals to allow for the sale and distribution of the COVID-19 Nucleic Acid Diagnostics Kits to regions within Europe and Asia as well as the USA.

Jitto Arulampalam
Chairman
Authorised by the Board of Directors
TBG Diagnostics Limited